---
figid: PMC7792690__AJ-AFLU200039F009
figtitle: Inhibition of 15-PGDH prevents ischemic renal injury by the PGE2/EP4 signaling
  pathway mediating vasodilation, increased renal blood flow, and increased adenosine/A2A
  receptors
organisms:
- Mus musculus
- Homo sapiens
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC7792690
filename: AJ-AFLU200039F009.jpg
figlink: /pmc/articles/PMC7792690/figure/F0009/
number: F9
caption: Shematic mechanism of intrarenal vasodilation by the 15-hydoxyprostaglandin
  dehydrogenase (15-PGDH) inhibitor (PGDH-i) in ischemic acute kidney injury. 15-PGDH
  inhibitor pretreatment increases endogenous PGE2 by inhibiting degradation of PGE2
  prior to an ischemic event in the kidney. Endogenous PGE2 induces vasodilation through
  the activated EP4 receptor. Activation of EP4 receptors increases the intracellular
  cAMP level in vascular smooth muscle cells and the effect on vasodilation. Increased
  cAMP is converted to the adenosine (ADO) substrate AMP, which, in turn, increases
  the endovascular adenosine level. ADO activates A2A receptors to induce vasodilation.
  On the other hand, nonsteroidal anti-inflammatory drugs (NSAIDs),cyclooxygenase
  (cox) inhibitors, lead to vasoconstriction, in contrast to the hemodynamic effects
  of 15-PGDH inhibitors. AA, arachidonic acid; ePDE, extracellular phosphodiesterase;
  RBC, red blood cell.
papertitle: Inhibition of 15-PGDH prevents ischemic renal injury by the PGE2/EP4 signaling
  pathway mediating vasodilation, increased renal blood flow, and increased adenosine/A2A
  receptors.
reftext: Hye Jung Kim, et al. Am J Physiol Renal Physiol. 2020 Dec 1;319(6):F1054-F1066.
year: '2020'
doi: 10.1152/ajprenal.00103.2020
journal_title: American Journal of Physiology - Renal Physiology
journal_nlm_ta: Am J Physiol Renal Physiol
publisher_name: American Physiological Society
keywords: acute kidney injury | adenosine | 15-hydoxyprostaglandin dehydrogenase |
  prostaglandin E2 | vasodilation
automl_pathway: 0.9406769
figid_alias: PMC7792690__F9
figtype: Figure
redirect_from: /figures/PMC7792690__F9
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7792690__AJ-AFLU200039F009.html
  '@type': Dataset
  description: Shematic mechanism of intrarenal vasodilation by the 15-hydoxyprostaglandin
    dehydrogenase (15-PGDH) inhibitor (PGDH-i) in ischemic acute kidney injury. 15-PGDH
    inhibitor pretreatment increases endogenous PGE2 by inhibiting degradation of
    PGE2 prior to an ischemic event in the kidney. Endogenous PGE2 induces vasodilation
    through the activated EP4 receptor. Activation of EP4 receptors increases the
    intracellular cAMP level in vascular smooth muscle cells and the effect on vasodilation.
    Increased cAMP is converted to the adenosine (ADO) substrate AMP, which, in turn,
    increases the endovascular adenosine level. ADO activates A2A receptors to induce
    vasodilation. On the other hand, nonsteroidal anti-inflammatory drugs (NSAIDs),cyclooxygenase
    (cox) inhibitors, lead to vasoconstriction, in contrast to the hemodynamic effects
    of 15-PGDH inhibitors. AA, arachidonic acid; ePDE, extracellular phosphodiesterase;
    RBC, red blood cell.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - APRT
  - MFAP1
  - NT5E
  - ADO
  - PTGER4
  - IGKV2D-29
  - COX8A
  - CPOX
  - COX5A
  - COX5B
  - COX6C
  - COX7C
  - .na.character
  - COX4I1
  - COX4I2
  - COX6A1
  - COX6A2
  - COX6B1
  - COX6B2
  - COX7A1
  - COX7A2
  - COX7B
  - COX7B2
  - COX8C
  - ALDH7A1
  - PDE2A
  - PDE9A
  - PDE10A
  - PDE11A
  - PDE1A
  - PDE1B
  - PDE1C
  - PDE3A
  - PDE3B
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - PDE6A
  - PDE6B
  - PDE6C
  - PDE7A
  - PDE7B
  - PDE8A
  - PDE8B
  - Nt5e
  - Ado
  - Ptger4
  - Adra2a
  - H2-Aa
  - Cox4i1
  - Twist1
  - poe
  - Amph
  - ado
  - aa
  - COX4
  - dnc
---
